Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Operating Income (2019 - 2025)

BridgeBio Pharma's Operating Income history spans 7 years, with the latest figure at -$139.6 million for Q4 2025.

  • For Q4 2025, Operating Income rose 38.25% year-over-year to -$139.6 million; the TTM value through Dec 2025 reached -$523.4 million, up 11.73%, while the annual FY2025 figure was -$523.4 million, 11.73% up from the prior year.
  • Operating Income for Q4 2025 was -$139.6 million at BridgeBio Pharma, up from -$145.2 million in the prior quarter.
  • Across five years, Operating Income topped out at $343000.0 in Q1 2024 and bottomed at -$226.0 million in Q4 2024.
  • The 5-year median for Operating Income is -$145.6 million (2023), against an average of -$140.6 million.
  • The largest annual shift saw Operating Income soared 100.27% in 2024 before it tumbled 30529.15% in 2025.
  • A 5-year view of Operating Income shows it stood at -$165.6 million in 2021, then rose by 21.97% to -$129.2 million in 2022, then plummeted by 37.28% to -$177.4 million in 2023, then fell by 27.4% to -$226.0 million in 2024, then soared by 38.25% to -$139.6 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Operating Income are -$139.6 million (Q4 2025), -$145.2 million (Q3 2025), and -$134.3 million (Q2 2025).